NCT06156982View on ClinicalTrials.gov

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan

CompletedOBSERVATIONAL
Enrollment

397

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
COVID-19
Interventions
DRUG

Evusheld

Administration of Evusheld 600 mg

Trial Locations (1)

Unknown

Research Site, Osaka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06156982 - An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan | Biotech Hunter | Biotech Hunter